Summaries of newly published research, clinical trial updates, and compound news.
Structure Therapeutics’ experimental pill aleniglipron just delivered strong Phase 2b weight-loss data. Here’s why its small-molecule design matters and how it stacks up against the GLP-1 pills already on shelves.
A year after Wegovy became the first GLP-1 approved for MASH, new AASLD clinical guidance and real prescribing data show what the ESSENCE trial results actually mean for the millions of Americans with fatty liver disease.
Oral semaglutide, Foundayo, and a pipeline of small-molecule challengers are all fighting for the same needle-averse patient. Here’s how every oral GLP-1 option compares, dosing rules and all.
BPC-157 just cleared a real hurdle — a favorable PCAC committee vote toward FDA’s 503A Bulk Drugs List — but it’s still not formally authorized for compounding. Here’s the full regulatory timeline and what’s still ahead.
The FDA’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list just finished its comment period. Here’s what changes, what doesn’t, and why the shortage-era compounding market is ending.
A new peer-reviewed study has quantified the long-term urinary metabolite M5-b of LGD-4033, also known as ligandrol, after controlled human micro-dose administration. The findings show dose-dependent excretion, several-day detection after a single exposure, and prolonged detectability after consecutive administration. The work does not make LGD-4033 safer or legal, but it gives anti-doping laboratories a stronger basis for interpreting low-level SARM findings and distinguishing possible exposure patterns.
Fifty-four thousand customers. Eighty countries. Five million dollars in proceeds. And a product that, when federal investigators finally tested it,
Somewhere between December 2024 and March 2025, officers at U.S. Customs and Border Protection’s Cincinnati port of entry started noticing
A July 2026 Gallup poll finds 11% of American adults now take a GLP-1 for weight loss, up from 3% in 2024 — while the national obesity rate has dropped to its lowest point since 2022.
CMS launched the Medicare GLP-1 Bridge on July 1, 2026 — a $50/month copay demonstration covering Wegovy, Zepbound, and Foundayo through 2027. Here’s exactly who qualifies and what’s actually covered.
